Supplementary material: Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

These are peer-reviewed supplementary materials for the article 'Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol' published in the Journal of Comparative Effectiveness Research.Table S1: Charlson comorbidity indexTable S2: CHA2DS2-VASc score for stroke risk in atrial fibrillationTable S3: HAS-BLED score for bleeding risk on oral anticoagulation in atrial fibrillationTable S4: Detail of unit costs and work disability (year 2021)Table S5: Baseline patient characteristics by study group (N = 32,925, without PSM)Table S6: ICD-9-CM and ICD-10-CM codes used to define the results (effectiveness)Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation (NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study on patients with NVAF who started their treatment with apixaban or acenocoumarol between 1 January 2015 and 31 December 2017. Results: 2160 patients treated with apixaban were paired (1:1) with patients treated with acenocoumarol (propensity score matching). Apixaban reduced the incidence of strokes and systemic embolisms, minor and major bleedings and deaths, versus acenocoumarol. Apixaban led to reductions of 80, 55 and 43% in costs related to nursing visits, hospitalizations, and emergency visits, respectively, leading to annual cost savings of €274/patient, from the perspective of society. Conclusion: Our results suggested that apixaban is a cost-effective alternative for patients with NVAF.

本数据集为发表于《比较疗效研究杂志》的论文《西班牙非瓣膜性心房颤动相关医疗资源和成本：阿哌沙班与华法林的比较》的同行评审补充材料。其中，表S1：查尔森合并症指数；表S2：心房颤动卒中风险CHA2DS2-VASc评分；表S3：心房颤动口服抗凝治疗出血风险HAS-BLED评分；表S4：2021年单位成本和工作残疾详情；表S5：按研究组划分的基线患者特征（N=32,925，未进行倾向性评分匹配）；表S6：用于定义结果（有效性）的ICD-9-CM和ICD-10-CM编码。研究目的：分析西班牙非瓣膜性心房颤动（NVAF）相关的医疗资源使用和成本。研究方法：本项研究为一项观察性和回顾性研究，研究对象为2015年1月1日至2017年12月31日期间开始使用阿哌沙班或华法林治疗的NVAF患者。研究结果：2160名接受阿哌沙班治疗的患者与接受华法林治疗的患者进行了1:1配对（倾向性评分匹配）。与华法林相比，阿哌沙班降低了中风和系统性栓塞、轻微和严重出血以及死亡的发生率。阿哌沙班导致护理访问、住院和急诊访问相关成本分别降低了80%、55%和43%，从而为社会节省了每年每人274欧元的成本。研究结论：我们的研究结果提示，阿哌沙班是非瓣膜性心房颤动患者的一种成本效益比高的替代治疗方案。